Home Cart 0 Sign in  
X

[ CAS No. 31891-06-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 31891-06-2
Chemical Structure| 31891-06-2
Chemical Structure| 31891-06-2
Structure of 31891-06-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 31891-06-2 ]

Related Doc. of [ 31891-06-2 ]

Alternatived Products of [ 31891-06-2 ]

Product Details of [ 31891-06-2 ]

CAS No. :31891-06-2 MDL No. :MFCD01566303
Formula : C7H9NO2S Boiling Point : -
Linear Structure Formula :- InChI Key :MKJQYFVTEPGXIE-UHFFFAOYSA-N
M.W : 171.22 Pubchem ID :1988156
Synonyms :

Calculated chemistry of [ 31891-06-2 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.29
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 44.81
TPSA : 80.56 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.9 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.93
Log Po/w (XLOGP3) : 2.03
Log Po/w (WLOGP) : 1.51
Log Po/w (MLOGP) : 0.64
Log Po/w (SILICOS-IT) : 1.96
Consensus Log Po/w : 1.41

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.32
Solubility : 0.822 mg/ml ; 0.0048 mol/l
Class : Soluble
Log S (Ali) : -3.35
Solubility : 0.0766 mg/ml ; 0.000447 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.78
Solubility : 2.82 mg/ml ; 0.0164 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.37

Safety of [ 31891-06-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 31891-06-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 31891-06-2 ]
  • Downstream synthetic route of [ 31891-06-2 ]

[ 31891-06-2 ] Synthesis Path-Upstream   1~6

  • 1
  • [ 31891-06-2 ]
  • [ 77287-34-4 ]
  • [ 14080-50-3 ]
YieldReaction ConditionsOperation in experiment
44% Reflux General procedure: The different ethyl 2-aminothiophene-3-carboxylate (5a-g) (1 eq.) and formamide (3.2mL/mmol eq.) were refluxed for 8 h. The reaction mixture was then cooled in an ice-bath and added of cold water. The precipitate formed was collected by filtration, washed thoroughly with cold water and purified by crystallisation from EtOH/H2O unless otherwise stated.
Reference: [1] European Journal of Medicinal Chemistry, 2016, vol. 123, p. 31 - 47
  • 2
  • [ 31891-06-2 ]
  • [ 56843-79-9 ]
Reference: [1] Patent: WO2017/31176, 2017, A1,
  • 3
  • [ 40018-26-6 ]
  • [ 105-56-6 ]
  • [ 31891-06-2 ]
YieldReaction ConditionsOperation in experiment
79% With triethylamine In 2,2,2-trifluoroethanol at 60℃; for 6.5 h; Microwave irradiation General procedure: In a 2–5 mL microwave vial was added the nitrile (0.22 mmol, 1 equiv) and trifluoroethanol (2 mL) which was stirring for 2 min to dissolve. Next, 1,4-dithian-2,5-diol (0.11 mmol, 0.5 equiv) was then added and stirred for 5 min before triethylamine(0.242 mmol; 1.1 equiv) was added and the mixture further stirred for 2 min. The vial was then sealed and heated in the microwave for 390 min at 60 °C. The solvent was evaporated under vacuo and the crude residue was then purified using flash chromatography on silica (EtOAc/hexanes).
64% With triethylamine In N,N-dimethyl-formamide at 45℃; for 1 h; Inert atmosphere Triethylamine (1.8 mL, 13.3 mmol) was added dropwise over 10 min. to a mixture of ethyl cyanoacetate(4) (3 g, 26.6 mmol) and 1,4-dithiane-2,5-diol (3) (2 g, 13.3 mmol) in anhydrous DMF (10 mL) at r.t. under N2 atmosphere. After the addition was complete the reaction mixture was heated at 45°C for 1 h. The reaction mixture was diluted with 0.4 M acetic acid (70 mL) and extracted with EtOAc (4 x 50 mL). The combined extracts were washed with water (2 x 100mL), dried over MgSO4, and concentrated in vacuo to give a crude brown oil that was purified by flash column chromatography (n-hexane-EtOAc100:0 v/v increasing to n-hexane-EtOAc 95:5 v/v) giving a colourless oil in 64percent yield. TLC (4:1 nhexane-EtOAc, Rf: 0.55). 1H-NMR (CDCl3), δ: 1.36 (t, J= 7.1 Hz, 3H), 4.29 (q, J= 7.1 Hz, 2H), 5.87 (bs,2H), 6.19 (d, J= 5.9 Hz, 1H), 6.99 (d, J= 5.9 Hz, 1H). 13C-NMR (CDCl3), δ: 14.5, 59.7, 106.8, 107.2,125.9, 162.9, 165.4.
Reference: [1] Synthesis (Germany), 2013, vol. 45, # 1, p. 45 - 52
[2] Journal of Medicinal Chemistry, 1999, vol. 42, # 26, p. 5437 - 5447
[3] Beilstein Journal of Organic Chemistry, 2015, vol. 11, p. 875 - 883
[4] Chemical Communications, 2013, vol. 49, # 2, p. 190 - 192
[5] Archiv der Pharmazie, 2011, vol. 344, # 7, p. 459 - 465
[6] Journal of Organic Chemistry, 2012, vol. 77, # 12, p. 5429 - 5433
[7] European Journal of Medicinal Chemistry, 2016, vol. 123, p. 31 - 47
[8] Patent: WO2009/1214, 2008, A2, . Location in patent: Page/Page column 48
  • 4
  • [ 105-56-6 ]
  • [ 31891-06-2 ]
YieldReaction ConditionsOperation in experiment
71% With morpholine; sulfur; triethylamine In ethanol; N,N-dimethyl-formamide at 90℃; General procedure: A mixture of cyclohexanone (1.06 mL, 10 mmol), ethyl cyanoacetate (1.15 mL, 10 mmol), morpholine (0.90 mL, 10 mmol), sulphur (0.32 g, 10 mmol) in ethanol (10 mL) was stirred and refluxed for overnight. After completion of the reaction, the reaction mixture was cooled to room temperature and the solvent was removed under vacuum. The crude solid was washed with cold ethanol and filtered though sintered funnel, dried under vacuum. The crude product was dissolved in dichloromethane and washed with brine. The organic layer was collected and concentrated under low vacuum to give the compound 2a; yield: 73percent (1.83 g);
Reference: [1] European Journal of Medicinal Chemistry, 2014, vol. 86, p. 270 - 278
[2] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 13, p. 4418 - 4427
  • 5
  • [ 67-56-1 ]
  • [ 56387-08-7 ]
  • [ 31891-06-2 ]
Reference: [1] European Journal of Medicinal Chemistry, 2014, vol. 76, p. 343 - 351
  • 6
  • [ 31891-06-2 ]
  • [ 117516-97-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 3, p. 597 - 603
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 31891-06-2 ]

Esters

Chemical Structure| 4651-81-4

[ 4651-81-4 ]

Methyl 2-aminothiophene-3-carboxylate

Similarity: 0.97

Chemical Structure| 59739-05-8

[ 59739-05-8 ]

tert-Butyl 2-aminothiophene-3-carboxylate

Similarity: 0.95

Chemical Structure| 43088-42-2

[ 43088-42-2 ]

Ethyl 2-amino-4-methylthiophene-3-carboxylate

Similarity: 0.94

Chemical Structure| 72965-16-3

[ 72965-16-3 ]

Ethyl 2-amino-4-isopropylthiophene-3-carboxylate

Similarity: 0.88

Chemical Structure| 56387-07-6

[ 56387-07-6 ]

Ethyl 2-amino-5-bromothiophene-3-carboxylate

Similarity: 0.82

Amines

Chemical Structure| 4651-81-4

[ 4651-81-4 ]

Methyl 2-aminothiophene-3-carboxylate

Similarity: 0.97

Chemical Structure| 59739-05-8

[ 59739-05-8 ]

tert-Butyl 2-aminothiophene-3-carboxylate

Similarity: 0.95

Chemical Structure| 43088-42-2

[ 43088-42-2 ]

Ethyl 2-amino-4-methylthiophene-3-carboxylate

Similarity: 0.94

Chemical Structure| 72965-16-3

[ 72965-16-3 ]

Ethyl 2-amino-4-isopropylthiophene-3-carboxylate

Similarity: 0.88

Chemical Structure| 56387-07-6

[ 56387-07-6 ]

Ethyl 2-amino-5-bromothiophene-3-carboxylate

Similarity: 0.82